Starting Smart: How To Structure An Integrated Supply Chain In Early-Stage CGT Programs

For small, science-driven teams in the early stages of cell and gene therapy (CGT) development, the primary focus is often on proof of concept, rather than logistics. But those behind-the-scenes decisions made before your first patient dose can have lasting implications on your ability to scale, meet regulatory requirements, and maintain consistent product quality. While it may be tempting to treat cold chain logistics and cryopreservation planning as tasks for a later phase, delaying these decisions can introduce serious risks and costly delays just when your program begins to show promise.

Explores what early-stage CGT programs need to know about building a scalable, compliant supply chain from day one. From understanding the unique challenges of CGT logistics to selecting the right cryopreservation strategy and vendor partnerships, every choice has a downstream impact. Learn how integrated supply chain partners can future-proof your operations, supporting you from first-in-human trials to full commercialization.